Cagrilintide Guide

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk for weight-management research. It is best known as the amylin component of CagriSema, an investigational fixed-dose combination that pairs cagrilintide with semaglutide, a GLP-1 receptor agonist. [1][5]

The evidence base is stronger than many research peptides discussed online because it includes randomized human trials. Still, cagrilintide should be understood as an investigational medicine candidate, not a consumer peptide with an approved label or public use instructions. [1][2][5][7]

Amylin is a pancreatic hormone co-secreted with insulin that participates in appetite, satiety, gastric-emptying, and post-meal glucose biology. Cagrilintide is designed as a longer-acting amylin analogue, meaning it is intended to engage this biology for a longer interval than native amylin. [1][5]

In obesity research, the practical hypothesis is that amylin-pathway activation may reduce hunger and increase fullness. Novo describes CagriSema as targeting complementary obesity-related pathways by combining cagrilintide with semaglutide, which acts through GLP-1 receptor signaling. [2][5]

Mechanistic plausibility is not the same as clinical proof. The most important questions remain outcome-based: how much body-weight change is seen, how durable it is, what adverse events occur, which populations were studied, and whether the benefit-risk profile supports approval. [1][2][3][5]

A 2021 Phase 2 Lancet trial studied once-weekly cagrilintide for 26 weeks in adults with overweight or obesity without diabetes. The trial reported dose-dependent body-weight reduction, with the highest cagrilintide group showing greater mean weight reduction than liraglutide in that study design. [1]

A 2021 Phase 1b Lancet trial evaluated cagrilintide co-administered with semaglutide in adults with overweight or obesity. It found that the combination was generally tolerated in the short trial, with gastrointestinal adverse events common, and it supported larger and longer studies rather than proving long-term clinical use. [2]

REDEFINE 1, a 68-week Phase 3 trial in adults with obesity or overweight without diabetes, evaluated CagriSema against placebo and individual components. Novo reported 20.4% mean body-weight reduction with CagriSema versus 3.0% with placebo using the treatment-policy estimand, and 22.7% versus 2.3% using the trial-product estimand. [3][5]

REDEFINE 2 studied adults with overweight or obesity and type 2 diabetes. Novo reported mean body-weight reduction of 13.7% with CagriSema versus 3.4% with placebo using the treatment-policy estimand, and 15.7% versus 3.1% using the trial-product estimand. [4][5]

Current development is still moving. Novo listed a CagriSema US decision milestone in Q4 2026 and a high-dose cagrilintide Phase 3 initiation milestone in its Q1 2026 investor materials, so status should be rechecked before publication. [7]

The strongest evidence-supported claim is weight-management potential in studied clinical-trial populations. Cagrilintide monotherapy produced clinically meaningful weight loss in Phase 2, and the CagriSema combination produced larger reductions in Phase 3 trials than placebo. [1][3][4][5]

Claims that cagrilintide is a simple add-on, safer replacement, or interchangeable substitute for approved medications go beyond the evidence. The CagriSema data are about a regulated investigational combination, studied with trial oversight and defined eligibility criteria. [3][4][5]

Claims about body composition, long-term maintenance, cardiometabolic outcomes, or cardiovascular event reduction need careful separation from body-weight endpoints. Some sub-analyses and ongoing trials are relevant, but they should not be treated as final outcome evidence until fully reported. [5][6]

Across cagrilintide and CagriSema studies, gastrointestinal adverse events are a central safety and tolerability theme. In Novo reporting for REDEFINE 1, adverse events were mainly gastrointestinal, including nausea, constipation, and vomiting, and were mostly transient and mild-to-moderate in severity. [2][5]

The Phase 1b combination trial reported many adverse events but most were mild to moderate, and the authors concluded that larger and longer trials were needed to fully assess efficacy and safety. That limitation matters because early tolerability does not settle uncommon, longer-term, or population-specific risks. [2]

CagriSema uses both amylin and GLP-1 biology. Any future label, if approved, would need to define contraindications, warnings, adverse reactions, storage requirements, and patient-selection rules. Until then, clinical-trial and company-reported data should not be converted into personal-use instructions. [5][7]

Products sold outside regulated channels as cagrilintide or CagriSema are not equivalent to trial material or an approved medicine. Identity, purity, potency, sterility, stability, and labeling may be unknown. [5]

There is no FDA-approved standalone cagrilintide prescribing label to cite for consumer storage, reconstitution, injection, route, or beyond-use instructions. The absence of an approved label is the key storage point for public readers. [5][7]

Clinical-trial storage and handling belong to study protocols, qualified site staff, and controlled supply chains. A seller-provided vial label or storage suggestion should not be treated as proof of quality, legality, sterility, or clinical appropriateness. [5][6]

If CagriSema is approved in the future, storage and handling should be taken from the official approved label for that exact product and region. It should not be inferred from research papers, online peptide-market guidance, or unrelated GLP-1 products. [5][7]